MicroPort International Corp. Limited
About MicroPort International Corp. Limited
MicroPort International Corp. Limited is a corporate venture capital firm based in Shanghai, China, focusing on investments in the medical technology sector. The firm is a subsidiary of MicroPort Scientific Corporation, a multinational medical technology company that designs and produces medical devices across multiple therapeutic areas, including interventional cardiology, orthopedics, cardiac rhythm management, electrophysiology, neurovascular intervention, structural heart disease, surgical robotics, and critical care. MicroPort International Corp. Limited primarily invests in early-stage to late-stage companies within the medical technology industry, with a particular emphasis on private equity and venture capital opportunities. The firm's investment strategy involves identifying and supporting innovative companies that align with MicroPort Scientific Corporation's mission to provide affordable life-saving solutions and treatments for patients. MicroPort International Corp. Limited has a diverse portfolio of investments in various medical technology sectors, including surgical robotics, cardiac rhythm management, and endovascular therapies. The firm's investments aim to enhance MicroPort Scientific Corporation's global presence and technological capabilities, contributing to the advancement of medical technologies worldwide. Through its strategic investments, MicroPort International Corp. Limited plays a crucial role in expanding MicroPort Scientific Corporation's reach and impact in the global medical device market, supporting the development and commercialization of cutting-edge medical technologies that address critical healthcare needs.
Investment Mandate
Investment Stages3
Asset Classes2
Industry Focus20
Geographical Focus
African markets2
Other stated markets18
Requirements
Innovative medical technology solutions, Alignment with MicroPort Scientific Corporation's mission, Potential for global market impact, Strong management teams, Scalable business models, Regulatory compliance, Clinical efficacy, Market readiness, Competitive differentiation, Sustainable growth potential
Stated Portfolio20
As reported by the investor. We hold no profile for these companies, so they are printed as stated rather than linked.
Is this you?
Claim this investor profile to manage your firm's information.
Claim this profileReport an error